AELIX THERAPEUTICS in collaboration with IrsiCaixa has developed a novel immunogen, termed HTI which was designed as an immunogen for T cells to be used as a a therapeutic HIV vaccine that could help HIV infected individuals to control viral replication in the absence of antiretroviral treatment. HTI is a chemically synthesized chimeric protein consisting of 16 continuous segments of HIV-1 each between 11 and 78 amino acids in length and encoding critical targets of viral proteins Gag (45%), Pol (44%), Vif (8%) and Nef (3%). The function of the immunogen HTI is the induction of an immune response by HIV-1-specific T cells directed against the regions included in the insert HTI, which can control HIV-1 effectively. The HTI immunogen is administered through an heterologous prime-boost vaccination that includes two components, a DNA vaccine prime (DNA.HTI) and a viral vaccine boost (MVA.HTI).